# Kurma Partners Kurma Partners is a Private Equity based in Paris, France. ## Overview - **Organization type:** Private Equity - **Headquarters:** Paris, France - **Region:** Europe - **Address:** Paris, France - **Founded:** 2009 - **Assets under management:** Undisclosed - **Website:** www.kurmapartners.com - **LinkedIn:** https://www.linkedin.com/company/kurma-life-sciences-partners ## Regulatory record - **Reports private funds:** No ## About Kurma Partners is a European venture capital group focused on healthcare and biotechnology investments. The company invests in various stages of company development, from creation to capital expansion. Kurma Partners collaborates with academic research institutions to build companies and provides funding and expertise to support their growth. ## Sectors - Biotech - AgTech - Healthtech ## People - Thierry Laugel — Managing Partner & Co-Founder - Rémi Droller — Managing Partner & Co-Founder ## Questions ### Who runs investment decisions at Kurma Partners? Managing Partners and co-founders Thierry Laugel and Rémi Droller lead the investment committee. Laugel previously founded a biotech company and brings operating CEO experience into deal evaluation, while Droller's background spans venture capital and scientific research. The broader partnership includes principals with PhDs and drug-development track records, giving the committee genuine bench depth when assessing preclinical assets. Final investment decisions rest with the managing partners. ### How does Kurma Partners source proprietary deal flow? Kurma's sourcing engine runs through long-term relationships with Europe's largest university-hospital systems, including Assistance Publique–Hôpitaux de Paris and similar networks in Germany, Switzerland, and the UK. The firm works directly with academic tech-transfer offices and principal investigators to identify research programs that need company-building capital and operational leadership. This academic-to-company funnel generates deal opportunities before the assets reach broader auction processes. The firm's Eurazeo backing gives it the institutional credibility to be the first call from a university licensing office. ### Does Kurma invest across the full biotech lifecycle or focus on one stage? Kurma operates three distinct fund strategies that together span the entire drug-development continuum. The Biofund series leads pre-seed and Series A rounds for companies still in preclinical or early clinical testing. The Diagnostics Fund targets molecular diagnostics and digital-health tools. Kurma Growth Opportunities provides larger growth-stage checks for companies approaching pivotal clinical trials or regulatory submissions. This structure allows the firm to back a company from formation through to a pharma trade sale without needing external co-investors to bridge stage transitions. ### Which sectors does Kurma Partners explicitly avoid? Kurma does not invest in medical devices, healthcare services, or consumer-health products. The firm's entire mandate is restricted to therapeutics, diagnostics, and adjacent digital-health tools that require regulatory approval and clinical validation. Within therapeutics, the firm has historically avoided me-too drug reformulations, preferring first-in-class or best-in-class biological approaches. The publication record shows no investments in companies focused predominantly on medical aesthetics or nutraceuticals. ### What is Kurma's known posture on co-investments alongside external GPs? Kurma actively co-invests with pharmaceutical venture arms and US-based life-science specialists, treating syndication as both a risk-management and relationship-building tool. The firm has co-invested alongside Novo Holdings, the corporate venture arm of Novo Nordisk, and with specialist funds like Jeito Capital. These relationships double as a future exit pathway, given that corporate venture arms often influence their parent companies' M&A pipelines. Kurma leads or co-leads its core Biofund rounds and takes active board seats, rather than passively following a lead investor. ### How is Kurma Partners related to Eurazeo? Eurazeo, the publicly traded Paris-based investment group, serves as a strategic partner and anchor limited partner in Kurma's funds, but the firm operates with an independent investment committee. The relationship dates to Kurma's founding in 2009, when Eurazeo provided the initial capital commitment and operational infrastructure support. This structure gives Kurma access to institutional-grade back-office functions without ceding investment autonomy. Eurazeo's own investor communications regularly highlight Kurma as a key portfolio holding within its asset-management segment (per Eurazeo annual reports). ## Related profiles - [Kurativz](https://altss.com/profile/kurativz) - [KUSABI](https://altss.com/profile/kusabi) --- Last updated: 2026-07-08T23:28:42.666Z Canonical page: https://altss.com/profile/kurma-partners Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology